2024
Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, PMCID: PMC11262662, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapy
2023
The Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States
Yaesoubi R, Xi Q, Hsu K, Gift T, St. Cyr S, Rönn M, Salomon J, Grad Y. The Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States. American Journal Of Epidemiology 2023, 193: 17-25. PMID: 37625444, PMCID: PMC10773484, DOI: 10.1093/aje/kwad175.Peer-Reviewed Original ResearchConceptsRapid drug susceptibility testDrug susceptibility testGonorrhea casesSusceptibility testsFirst-line treatmentBurden of gonorrheaGonococcal infectionGonorrhoea transmissionAntibiotic treatmentPatient outcomesIndividualized treatmentLife spanDrug susceptibilityCare testRapid pointEffective life spanAntibiotic resistanceAntibioticsTest specificityGonorrheaMenCiprofloxacinTreatmentCorrect ascertainmentLong-term impactResistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study
Reichert E, Yaesoubi R, Rönn M, Gift T, Salomon J, Grad Y. Resistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study. The Lancet Microbe 2023, 4: e781-e789. PMID: 37619582, PMCID: PMC10865326, DOI: 10.1016/s2666-5247(23)00145-3.Peer-Reviewed Original ResearchConceptsPrevalence of resistancePrimary outcomeGonococcal infectionGonorrhea treatmentCombination therapyAntibiotic resistanceResistance emergenceNew antibioticsNew drugsUrgent public health concernCombination therapy strategiesSexual activity groupsPopulation-level prevalencePublic health concernSecondary outcomesAnnual incidenceGonorrhoea transmissionCurrent therapiesMSM populationUS CentersMathematical modelling studyCurrent drugsUS populationNeisseria gonorrhoeaeInfectious diseases
2022
Evaluating spatially adaptive guidelines for the treatment of gonorrhea to reduce the incidence of gonococcal infection and increase the effective lifespan of antibiotics
Yaesoubi R, Cohen T, Hsu K, Gift TL, St. Cyr SB, Salomon JA, Grad YH. Evaluating spatially adaptive guidelines for the treatment of gonorrhea to reduce the incidence of gonococcal infection and increase the effective lifespan of antibiotics. PLOS Computational Biology 2022, 18: e1009842. PMID: 35139073, PMCID: PMC8863219, DOI: 10.1371/journal.pcbi.1009842.Peer-Reviewed Original ResearchConceptsIncidence of gonorrhoeaTreatment guidelinesResistance prevalenceGonorrhea casesTreatment of gonorrheaNational surveillance systemPrevalence of resistanceTransmission dynamic modelGonococcal infectionGonorrhea treatmentMSM populationAntibiotic susceptibilityGonorrheaStandardized guidelinesSurveillance dataPrevalenceIncidenceAntibioticsPotential strategySurveillance systemAbsence of pointsGuidelinesCurrent strategiesEffective lifespanMen